Martini et al. have also investigated the expression of EphA2 in other colorectal cancer cell lines, including SW620, LOVO, SW480, and HCT15, as well as in cell lines resistant to the anti-EGFR antibody cetuximab, such as GEO-CR and SW48-CR, and in cetuximab-sensitive cell lines, GEO and SW48. Here, EPHA2 is linked to colorectal cancer.